Crossmark

TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance

Crossref DOI link: https://doi.org/10.15252/emmm.201606370

Published Online: 2016-07-08

Published Print: 2016-09

Update policy: https://doi.org/10.1002/crossmark_policy

Authors

Xiang, Xianyuan

Werner, Georg

Bohrmann, Bernd

Liesz, Arthur

Mazaheri, Fargol

Capell, Anja

Feederle, Regina

Knuesel, Irene

Kleinberger, Gernot

Haass, Christian https://orcid.org/0000-0003-2629-0723
Funding

Funding for this research was provided by:

Deutsche Forschungsgemeinschaft (EXC 1010 SyNergy)

European Research Council (ERC grant Agreement No. 321366‐Amyloid)

MetLife Foundation

Cure Alzheimer's Fund
License Information

Version of Record valid from 2016-07-08
More Information

Publication History

Received: 2016-03-10

Accepted: 2016-06-10

Published: 2016-07-08